Sugammadex, a modified γ-cyclodextrin, is known to rapidly and completely reverse rocuronium and vecuronium in a dose-related manner [1] [2] [3] . In Australia, this drug is being used more frequently instead of the neostigmine/glycopyrrolate combination. Some centres have relatively unrestricted access to its use 4, 5 . Though there are reports supporting its safety and efficacy 6, 7 , in many countries it is still not available. For example, the United States Food and Drug Administration has not yet approved its use, due to safety concerns related to possible hypersensitivity and other allergic reactions 8 . This case report is a reminder that the use of sugammadex is not without its risks.
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Consent to publish the information and photographs was obtained from the patient. A 56-year-old man was undergoing open aorto-bifemoral bypass surgery for a large (9.6 cm) abdominal aortic aneurysm. His comorbidities included hypertension and hypercholesterolaemia, for which he was on regular medications. He had no history of previous drug allergy or previous sugammadex exposure. On arrival in the operating room, a lower thoracic epidural catheter was placed with aseptic precautions. Radial arterial cannulation and ultrasound-guided central venous catheter insertion were performed and standard anaesthetic monitoring was initiated. The patient was pre-oxygenated and anaesthesia was induced with propofol 200 mg and fentanyl 300 μg. Upon loss of consciousness, the patient was paralysed with rocuronium 50 mg. After two minutes of mask ventilation, the trachea was intubated and the airway secured. Anaesthesia was maintained with desflurane in oxygen-enriched air. An epidural bolus of 10 ml 0.2% ropivacaine was given pre-induction and an infusion of 0.2% ropivacaine with fentanyl 2 μg/ml was commenced at a rate of 10 ml/hour early during the procedure. Other drugs administered were cephazolin, granisetron, droperidol, dexamethasone and heparin. Suprarenal aortic cross-clamp time was 19 minutes. The right and left lower limbs were reperfused after 36 minutes and 50 minutes respectively. A repeat dose of rocuronium 20 mg was administered while the aorta was cross-clamped. The total estimated blood loss was 990 ml, of which 250 ml was returned to the patient using a cell saver. During the procedure, 2 litres of crystalloid and 1 litre of 4% albumin were given and the patient was believed to be normovolaemic on the basis of systemic blood pressure, pulse pressure variation and central venous pressure measurements.
At the end of surgery sugammadex 200 mg was administered to reverse the rocuronium-induced neuromuscular block. One minute later, the patient was in severe circulatory shock (systemic blood pressure 40/30 mmHg) associated with tachycardia (heart rate 104/minute). Airway pressure was unchanged and there were no skin manifestations.
SUMMARy
We describe a case of a patient undergoing open abdominal aneurysm surgery who developed a severe, lifethreatening allergic reaction immediately after administration of sugammadex. The manifestation was purely a cardiovascular collapse. The mainstay of treatment was administration of high-dose adrenaline and fluid resuscitation. The diagnosis of anaphylaxis was supported by a positive serum mast cell tryptase (93 μg/l) at one hour post-event. Sugammadex was confirmed as the cause of the anaphylaxis by a positive intradermal allergy test (25 mm diameter response to 1:100 dilution), with a normal saline control and a negative response to the other drugs used during the event. This case report is a reminder that the use of sugammadex is associated with rare but serious risks.
Key Words: sugammadex, anaphylaxis Sugammadex allergy was suspected and the surgeon was notified. Immediate treatment included 100% oxygen, fluid resuscitation and boluses of adrenaline in 200 μg aliquots intravenously. The blood pressure continued to be critically low for about ten minutes (Figure 1) . A total of 3 mg adrenaline was used as boluses and then an infusion of adrenaline commenced at 100 μg/minute. The surgeon reopened the abdomen and exposed the retroperitoneum to exclude any bleeding from the graft anastomotic sites, which turned out to be negative. This was undertaken without any further muscle paralysis. A second arterial line was placed in the other arm to confirm the true low blood pressure reading. After 20 minutes of resuscitation with adrenaline boluses and fluids (2 litres crystalloid and 1 litre synthetic gelatin), the patient's blood pressure returned to an acceptable level (Figure 1 ). The adrenaline infusion was reduced slowly over four hours and then ceased. The patient subsequently made an uneventful recovery.
The serum mast cell tryptase at one hour postincident was elevated to 93 μg/l. The patient had allergy testing six weeks later. Intradermal allergy testing was performed using both 1:100 (1 mg/ml) and 1:1000 (0.1 mg/ml) dilutions of the standard 100 mg/ml sugammadex solution. Both showed a positive wheal reaction measuring 25 mm and 15 mm respectively. Tests of other drugs used around the time of administration of sugammadex were negative (Figure 2 ).
DISCUSSION
There are only a few confirmed reports of allergic reactions to sugammadex in the literature, and the presentation has varied in severity from skin manifestations to bronchospasm and cardiovascular collapse 9, 10 . This case is remarkable on the basis of its severity and its purely cardiovascular nature. A possible confounding factor for the severity of the cardiovascular collapse could be the sympathetic blockade caused by epidural anaesthesia. However, the fluid resuscitation and alpha effects of high doses of adrenaline should have overcome the hypotension caused by central neuraxial blockade, suggesting that central neuraxial blockade was not a major factor in the severity of the presentation. It may be noted that once anaphylaxis occurs, the principles of treatment are the same irrespective of the cause and the confounding factors. On the basis of this and other case reports, sugammadex allergy appears to be occurring on first exposure, suggesting that there may be possible environmental sensitising agents predisposing to allergic reactions, as observed with neuromuscular blocking agents 11 . It would be interesting to see whether sugammadex anaphylaxis also occurs secondary to prior exposure. Future studies could focus on identifying the risk factors of preoperative sensitisation and possible screening.
In previous reports, positive skin-prick test results were obtained with a sugammadex dilution of 1:10 in one patient and 1:1000 in the other 9 . The British Society for Allergy and Clinical Immunology has given recommendations for both intradermal and skin-prick allergy tests for most anaesthetic drugs 12 . However, a specific recommendation on sugammadex dilution for allergy testing is still lacking. Since there are no data to suggest that one test is superior to the other 12, 13 , we chose intradermal testing based on other factors such as feasibility and experience. Also, we tested both 1:100 and 1:1000 dilutions. Our observation in this patient with true sugammadex allergy is that even a 1:1000 dilution appears to be sufficient to elicit a positive wheal response (15 mm).
Undoubtedly, sugammadex offers significant benefits and is changing our clinical practice, offering greater flexibility in the use of muscle relaxants. However, the safety aspect still needs further investigation. The current true perioperative anaphylaxis mortality is perhaps less than previously thought, but may still be up to 1.4% 14 . Moreover, anaphylaxis is always stressful, and may be associated with significant morbidity, treatment delays and increased costs. This implies that administration of sugammadex is not without risks. With a few cases of proven sugammadex anaphylaxis reported until now, and considering possible under-reporting, anaesthetists may want to consider tailoring its use to specific clinical situations rather than using it as a routine replacement for neostigmine/glycopyrrolate.
